[3S13m] Updated issues on Alport syndrome research | APPW2025

Session Details

Symposium

[3S13m]Updated issues on Alport syndrome research

Wed. Mar 19, 2025 8:30 AM - 10:20 AM JST
Wed. Mar 19, 2025 11:30 PM - 1:20 AM UTC

Room 13

Oranizers :Hirofumi Kai (Kumamoto University) and Kandai Nozu (Kobe University)

Drug development for chronic kidney disease is a major societal challenge. To date, pharmacological drug discovery strategies of national and international pharmaceutical companies have been developed using mouse models of Alport syndrome. In this symposium, international Alport syndrome researchers will present their latest research findings and discuss drug discovery strategies.

8:32 AM - 8:50 AM JST(11:32 PM - 11:50 PM UTC)

[[OD]3S13m-1]Current Status and Challenges in the Development of Therapeutics for Alport Syndrome

^○Kandai Nozu (Kobe University)

Comment()

8:50 AM - 9:15 AM JST(11:50 PM - 12:15 AM UTC)

[[OD]3S13m-2]Genetic Associations with Hematuria Highlight Type IV Collagen

^○Moumita Barua (Toronto General Hospital)

Comment()

9:15 AM - 9:40 AM JST(12:15 AM - 12:40 AM UTC)

[[OD]3S13m-3]Manipulation of the Kidney Glomerular Filtration Barrier and Implications for Alport Syndrome

^○Jeffrey Miner¹, Kohei Omachi², Meei-Hua Lin¹ (1.Washington University School of Medicine, 2.RIKEN Center for Biosystems Dynamics Research, Kobe)

Comment()

9:40 AM - 10:05 AM JST(12:40 AM - 1:05 AM UTC)

[[OD]3S13m-4]Basement membrane dynamics in Alport syndrome

^○Rachel Lennon (University of Manchester)

Comment()

10:05 AM - 10:20 AM JST(1:05 AM - 1:20 AM UTC)

[[OD]3S13m-5]A novel NRF2 activator added to angiotensin receptor blocker attenuates progressive phenotype in Experimental Alport Syndrome

^○Hirofumi Kai (Global Center for Natural Resources Sciences, Kumamoto University)

Comment()

Back to Category List